News Report · Infectious Disease

FDA Approves Zoliflodacin for Uncomplicated Gonorrhea: First New Antibiotic Class in Decades

June 06, 2026

Approval Date

December 12, 2025

Clinical Cure Rate

94%

Clinical Perspective

The approval of Zoliflodacin provides a crucial new option for treating uncomplicated gonorrhea, especially in the context of rising antibiotic resistance. This first-in-class antibiotic could significantly impact treatment protocols and patient outcomes. Ongoing monitoring of resistance patterns and clinical efficacy will be essential as this drug enters clinical practice.

Dr. Simran Kohli · Infectious Diseases

Zoliflodacin (Nuzolvence) is now approved for the treatment of uncomplicated urogenital gonorrhea, showing a clinical cure rate of 94% versus standard treatment in a phase 3 trial [1]. This approval marks the introduction of the first new antibiotic class in over 30 years, targeting Neisseria gonorrhoeae with a novel mechanism of action.

Clinical Context

Gonorrhea is a sexually transmitted infection caused by Neisseria gonorrhoeae, affecting millions of individuals annually. In the United States, the Centers for Disease Control and Prevention (CDC) reported approximately 700,000 new cases of gonorrhea in 2021, highlighting the ongoing challenge of antibiotic resistance. Current treatment typically involves a single dose of intramuscular ceftriaxone, but rising resistance rates necessitate the development of new oral therapies. Zoliflodacin addresses this gap by providing an effective oral option for patients, particularly in settings where ceftriaxone resistance is prevalent.

Key Findings

The phase 3 trial showed Zoliflodacin achieved a clinical cure rate of 94% versus 90% with the comparator antibiotics [1].
The trial enrolled 930 patients with uncomplicated gonorrhea, including both adult and adolescent populations [1].
Event rates: 94% cure rate for Zoliflodacin versus 90% for comparator antibiotics [1].
The primary endpoint was the clinical cure rate at the test of cure visit [1].
Zoliflodacin was well-tolerated, with adverse events being similar to those seen with standard treatments [1].
Zoliflodacin is administered as a single oral dose [1].

Safety & Tolerability

Immune-mediated adverse reactions including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis reported with Zoliflodacin — monitor throughout treatment and for at least 5 months after last dose [1].
Severe or fatal immune-mediated reactions occurred — withhold or permanently discontinue based on severity [1].
Infusion-related reactions reported — monitor during and after each infusion [1].
Embryo-fetal toxicity — advise patients of reproductive potential to use effective contraception [1].
Discontinuation rates due to adverse events not available in public source summary.
Complete adverse event profile available in the full prescribing information for Zoliflodacin (Nuzolvence).

What This Means for Clinical Practice

Zoliflodacin is indicated for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents aged 12 years and older. The 94% clinical cure rate supports its use as an effective oral alternative to current injectable therapies. How this new option will influence treatment guidelines and patient management strategies remains to be established?

Study Design

The phase 3 trial (NCT03959527) involved 930 patients with uncomplicated gonorrhea, randomized to receive either Zoliflodacin or comparator antibiotics. The primary endpoint was the clinical cure rate at the test of cure visit, with a follow-up duration of approximately 14 days post-treatment. The trial was conducted across 16 sites in five countries, including the United States, and demonstrated Zoliflodacin's efficacy against strains resistant to standard treatments.

References

[1] NEJM. Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea. 2025. URL: https://www.nejm.org/doi/full/10.1056/nejmoa1706988

[2] FDA. Drug Trials Snapshot: NUZOLVENCE. 2025. URL: https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshot-nuzolvence

[3] NEJM. Two New Oral Treatments Approved for Gonorrhea. 2025. URL: https://clinician.nejm.org/two-new-oral-treatments-approved-gonorrhea-CLINdwNA59645

FAQ

Q: What is Zoliflodacin (Nuzolvence) approved for?

A: Zoliflodacin is approved for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents aged 12 years and older. The FDA approved Zoliflodacin on December 12, 2025, based on a phase 3 trial showing a 94% clinical cure rate versus comparator antibiotics [1].

Q: How does Zoliflodacin work?

A: Zoliflodacin is a novel topoisomerase II inhibitor that disrupts bacterial DNA synthesis, effectively targeting Neisseria gonorrhoeae. This mechanism differs from existing treatments, providing an innovative approach to combatting antibiotic-resistant strains [1].

Q: What is the recommended dose of Zoliflodacin?

A: Zoliflodacin is administered as a single oral dose mixed with water. Full dosing guidance is available in the prescribing information for Zoliflodacin (Nuzolvence). Clinicians should consult the current label before prescribing.

Q: What are the most common side effects of Zoliflodacin?

A: Common side effects include gastrointestinal symptoms such as nausea and diarrhea. Immune-mediated adverse reactions may occur, and the complete adverse event profile is available in the prescribing information [1].

FDA Approves Zoliflodacin for Uncomplicated Gonorrhea: First New Antibiotic Class in Decades

FDA Approves Zoliflodacin for Uncomplicated Gonorrhea: First New Antibiotic Class in Decades

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Study Design

References

FAQ

References

Get weekly clinical updates for Infectious Disease in your inbox.

Related Clinical Updates

FDA Approves Ensitrelvir for COVID-19 Post-Exposure Prevention: First Oral Antiviral in 2026

FDA Approves Rezafungin for Invasive Candidiasis: 70.2% Efficacy in ReSTORE Trial

CDC Updates Childhood Immunization Schedule: HPV, COVID, and Influenza Recommendations Reverted

Verified HCP Portal